Hims (HIMS): FY26 Q2 earnings call, Aug 10, 2026
On its Aug 10, 2026 earnings call (FY26 Q2), Hims said 16 of the 25 words Kalshi and Polymarket listed; Parrot’s count agreed with all 25 settlements. Quotes below are at most 25 words each.
UpdatedMarkets
25 words · 16 settled yes · our count agreed on 25 of 25- Kalshi: company speakers + operator
Kalshi - Polymarket: anyone
Polymarket
backtest The probabilities on settled rows are a walk-forward backtest: the model as of before each event, computed after Parrot went live; they were not published at the time.
| Word | Result | Our count | All speakers | Agrees | Probability | Market |
|---|---|---|---|---|---|---|
| Quarter 20+ times | Yes | 52 | 52 | ✓ | 78%transcripts from the transcript model | – |
| Platform 10+ times | Yes | 45 | 45 | ✓ | 86%transcripts from the transcript model | – |
| Subscriber 15+ times | Yes | 22 | 22 | ✓ | 75%transcripts from the transcript model | – |
| Peptide 5+ times | Yes | 17 | 17 | ✓ | 59%transcripts from the transcript model | – |
| Peptide | Yes | 15 | 17 | ✓ | 91%n=3+tx from settlement history blended with transcripts | – |
| Testosterone | Yes | 13 | 13 | ✓ | 92%n=3+tx from settlement history blended with transcripts | – |
| Eucalyptus | Yes | 12 | 19 | ✓ | 77%transcripts from the transcript model | – |
| FDA | Yes | 7 | 8 | ✓ | 84%n=3+tx from settlement history blended with transcripts | – |
| Longevity | Yes | 5 | 5 | ✓ | 79%transcripts from the transcript model | – |
| Lab Testing | Yes | 4 | 4 | ✓ | 89%n=3+tx from settlement history blended with transcripts | – |
| Canada | Yes | 4 | 4 | ✓ | 84%n=3+tx from settlement history blended with transcripts | – |
| Wearable | Yes | 2 | 2 | ✓ | 70%transcripts from the transcript model | – |
| Wegovy | Yes | 2 | 2 | ✓ | 69%transcripts from the transcript model | – |
| Collaboration | Yes | 2 | 2 | ✓ | 65%n=3+tx from settlement history blended with transcripts | – |
| Europe | Yes | 2 | 2 | ✓ | 46%n=3+tx from settlement history blended with transcripts | – |
| GLP-1 | Yes | 1 | 1 | ✓ | 95%transcripts from the transcript model | – |
| Fiscal 10+ times | No | 2 | 2 | ✓ | 6%transcripts from the transcript model | – |
| Zava | No | 0 | 0 | ✓ | 88%n=3+tx from settlement history blended with transcripts | – |
| YourBio | No | 0 | 0 | ✓ | 61%transcripts from the transcript model | – |
| Vitamin | No | 0 | 0 | ✓ | 51%n=3+tx from settlement history blended with transcripts | – |
| Cancer | No | 0 | 0 | ✓ | 46%n=2+tx from settlement history blended with transcripts | – |
| Tariff | No | 0 | 0 | ✓ | 29%n=3+tx from settlement history blended with transcripts | – |
| Amazon | No | 0 | 0 | ✓ | 27%n=3+tx from settlement history blended with transcripts | – |
| Microdose / Microdosing | No | 0 | 0 | ✓ | 19%n=2+tx from settlement history blended with transcripts | – |
| Regulation | No | 0 | 0 | ✓ | 15%n=3+tx from settlement history blended with transcripts | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Oct 21, 2026 04:22 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
4 matches for “Lab Testing”; 4 quoted, at least 25 words apart.
…in higher complexity categories. Over 1 million square feet of pharmacy and lab testing facilities, deep expertise in sterile compounding, and a global reach. Our…
…beyond weight. Cross-sell potential increases further as we extend the reach of lab testing on our platform, which can surface underlying needs for treatment within…
…360 person's health, whether that's wearable data, our own devices, external devices, lab testing data, our own labs, external labs, all the way to preventative…
…and the clinical needs exist. Really core to this strategy was the lab testing infrastructure that we acquired and have rolled out in the last…
Where the listed words were said
Good afternoon, everyone, and welcome to the Hims & Hers Health second quarter 2026 earnings call. On the call with me today is Andrew Dudum,…
…global reach, when paired with our technology and infrastructure, has created a platform that shows customers and industry leaders alike that access to high-quality care…
…for customers everywhere. in the second quarter, we welcomed more than 300,000 subscribers, bringing our global subscriber base to nearly 3 million people. To put…
…and expand our offerings in categories like hormonal health, longevity medicine, and peptide therapy. His participation at the recent PCAC hearing demonstrated just how valuable…
…infrastructure, and ecosystem thrive. We are currently developing a best-in-class peptides experience, including U.S.-manufactured products, clinical-led guidance, and ongoing blood testing.…
…proactive about more complex health challenges that often go unseen or ignored. Testosterone is a powerful example. Most men experiencing low testosterone don't know it,…
…the leading global consumer health platform when we closed our acquisition of Eucalyptus. This was the largest acquisition in our company's history, and we now…
…them to the market with a safe, verified supply chain if the FDA decides to allow them for compounding. In the meantime, we plan to…
…Hims side of the house, who is an expert across hormonal therapy, longevity, and peptide therapy. He's been building out the clinical protocols, the guardrails,…
…are each already generating more than $100 million in annualized revenue, with Canada also on track to join this group as well as we scale…
…& Hers customer experience can look like. He asked, "Between labs, potential wearable partnerships, and the treatment and outcome data you're collecting from millions of…
…in which we can broaden access to patients in the U.S. The Wegovy pill has had a staggering launch. I think we are the largest…
Agents: this page as TSV at /api/v1/appearances/hims:2026-08-10:earnings_call · words: /api/v1/brief?appearance=hims:2026-08-10:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP